Gene-based delivery of IFN-β is efficacious in a murine model of experimental allergic encephalomyelitis

Journal of Interferon and Cytokine Research

Volumn 26, Issue 7, 2006, Pages 449-454

  Schaefer, Caralee ^a   Hidalgo, Toni Rose ^a   Cashion, Linda ^a   Petry, Harald ^a   Brooks, Alan ^a   Szymanski, Paul ^a   Qian, Hu Sheng ^a   Gross, Cynthia ^a   Wang, Peiyin ^a   Liu, Perry ^a   Goldman, Claudia ^a   Rubanyi, Gabor M ^a   Harkins, Richard N ^a  

^a BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; PLASMID DNA; PLASMID VECTOR; PREDNISOLONE; RNA;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNOMODULATION; INTERFERON PRODUCTION; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GENE TARGETING; GENE THERAPY; INTERFERON-BETA; MICE; MULTIPLE SCLEROSIS; PLASMIDS;

ANIMALIA; MURINAE;

EID: 33745943020     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2006.26.449     Document Type: Article

References (22)

1. Keegan BM, Noseworthy JH. Multiple sclerosis. Annu. Rev. Med. 2002;53:258-302.
2. Noseworthy J, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N. Engl. J. Med. 2000;343:938-952.
3. Walther EU, Hohlfeld R. Multiple sclerosis: side effects of Interferon beta therapy and their management. Neurology 1999; 53:1622-1627.
4. Bayas A, Gold R. Lessons from 10 years of interferon beta-1b (Betaferon/Betaseron) treatment. J. Neurol. 2004;250 (Suppl. 4): IV3-IV8.
5. Malucchi SM, Sala A, Gilli F, Bottero R, Di Sapio A, Capobianco M, Bertolotto A. Neutralizing antibodies reduce the efficacy of βIFN during treatment of multiple sclerosis. Neurology 2004; 62:2031-2037.
6. Wils R. Clinical pharmacokinetics of interferons. Clin. Pharmacokinet, 1990;19:390-399.
7. Salmon, P, Le Cotonnec J-Y, Galazka A, Abdul-Ahad A, Darragh A. Pharmacokinetics and pharmacodynamics of recombinant human interferon-β in healthy male volunteers. J. Interferon Cytokine Res. 1996;16:759-764.
8. Buchwalder P-A, Buclin, T, Trinchard I, Munafo A, Biollaz J. Pharmacokinetics and pharmacodynamics of IFN-β1a in healthy volunteers. J. Interferon Cytokine Res. 2000;20:57-66.
9. Hertz F, Degeghi R. Effect of rat and human β interferons on hyperacute experimental allergic encephalomyelitis. Agents Actions 1985;16:397-403.
10. Abreu S. Interferon in experimental autoimmune encephalomyelitis (EAE): effects of exogenous interferon on the antigen-enhanced adoptive transfer of EAE. Int. Arch. Allergy Appl. Immunol. 1985;76:302-307.
11. Yu M, Nishiyama A, Trapp BD, Tuohy VK. Interferon β inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis. J. Immunol. 1996;64:91-100.
12. Tuohy VK, Yu M, Yin L, Mathisen PM, Johnson JM, Kawczak JA. Modulation of the IL-10/IL-12 cytokine circuit by interferon-beta inhibits the development of epitope spreading and disease progression in murine autoimmune encephalomyelitis. J. Neuroimmunol. 2000;111:55-63.
13. Hallal DEM, Farias AS, Oliveira EC, Diaz-Bardales BM, Brandao CO, Protti GG, Pereira FG, Metze IL, Santos LMB. Costimulatory molecule expression on leukocytes from mice with experimental autoimmune encephalomyelitis treated with IFN-β. J. Interferon Cytokine Res. 2003;23:293-298.
14. Triantaphyllopoulos K, Croxford J, Baker D, Chernajovsky Y. Cloning and expression of murine IFNβ and a TNF antagonist for gene therapy of experimental allergic encephalomyelitis. Gene Ther. 1998;5:253-263.
15. Croxford JL, Triantaphyllopoulos KA, Podhajcer OL, Feldmann M, Baker D, Chernajovsky Y. Cytokine gene therapy in experimental allergic encephalomelitis by injection of plasmid DNA-cationic liposome complex into the central nervous system. J. Immunol 1998;160:5181-5187.
16. Hardy MP, Owczarek CM, Trajanovska S, Liu X, Kola I, Hertzog PJ. The soluble murine type I interferon receptor 1FNAR-2 is present in serum, is independently regulated, and has both agonistic and antagonistic properties. Blood 2001;97:473-482.
17. Teige I, Treschow A, Teige A, Mattsson R, Navikas V, Leanderson T, Holmdahl R, Issazadeh-Navikas S. 1FN-β gene deletion leads to augmented and chronic demeylinating experimental autoimmune encephalomyelitis. J. Immunol. 2003;170:4776-4784, 2003.
18. Prud'homme GJ. Gene therapy of autoimmune diseases with vectors encoding regulatory cytokines or inflammatory cytokine inhibitors. J. Gene Med. 2000;2:222-232.
19. Chernajovsky Y, Could DJ, Podhajcer OL. Gene therapy for autoimmune diseases: Quo vadis? Nature Rev. Immunol. 2004; 4:800-811.
20. Goetschy JF, Zeller H, Content J, Horisberger MA. Regulation of the interferon-inducible IFI-78K, human equivalent of the murine Mx gene, by interferons, double stranded RNA, certain cytokines and viruses. J. Virol. 1989;63:2616-2622.
21. Von Wussow P, Jakschies D, Block B, Hochkeppel HK, Fibich C, Penner L, Deicher H. The human intracellular Mx-homologous protein is specifically induced by type 1 interferons. Eur. J. Immunol. 1990;20:2015-2019.
22. Petry H, Cashion L, Szymanski P, Ast O, Orme A, Gross C, Bauzon M, Brooks A, Schaefer C, Gibson H, Qian HS, Rubanyi G, Harkins R. Mx1 and IP-10: biomarkers to measure interferon-β activity in mice following gene-based delivery. J. Interferon Cytokine Res. 2006; in press.